Literature DB >> 30328570

Therapy to Obese Type 2 Diabetes Mellitus: How Far Will We Go Down the Wrong Road?

Xian-Pei Heng1, Xiu-Jun Li2, Liang Li3, Liu-Qing Yang3, Zi-Ta Wang3, Su-Ping Huang4.   

Abstract

Traditional glucose-lowering chemical agents, including various types of insulin and insulin secretagogues, insulin sensitizers, gliptins, etc., are based on diabetic pathogenesis of insulin resistance (IR) and islet insufficiency. Numerous evidence-based medical studies have shown that these traditional hypoglycemic chemical agents do not provide cardiovascular benefit to patients with type 2 diabetes mellitus (T2DM) and may even increase the risk of all-cause mortality. Based on research evidence published to date, these studies show that overload of energy could increase the incidence and prevalence of T2DM, and reduction in the heat load can significantly reduce the incidence of T2DM. Therefore, the essence of T2DM is heat overload, meaning heat overload is the etiology of obese T2DM. At the same time, results of numerous studies show that heat overloading is the cause of IR. IR and islet dysfunction are protective factors in intervening with heat overload. These drugs, which are based on the mechanisms of IR and islet insufficiency, increase caloric reserve and cause or worsen obesity, which is equivalent to exacerbating the basic etiology and the cardiovascular risk factor of T2DM. Thus, a reasonable strategy for prevention and treatment of obese T2DM appears to promote the negative balance of calories and the elimination of caloric reserves. Chinese herbal medicines can promote negative balance of heat in many aspects, which can bring new hope for prevention and treatment of T2DM.

Entities:  

Keywords:  Chinese herbal medicine; etiology; obese type 2 diabetes mellitus; prevention and treatment

Mesh:

Substances:

Year:  2018        PMID: 30328570     DOI: 10.1007/s11655-018-3053-8

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  70 in total

1.  Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis.

Authors:  E S Mearns; W J Saulsberry; C M White; C G Kohn; S Lemieux; A Sihabout; I Salamucha; C I Coleman
Journal:  Diabet Med       Date:  2015-07-17       Impact factor: 4.359

2.  Prevalence and control of diabetes in Chinese adults.

Authors:  Yu Xu; Limin Wang; Jiang He; Yufang Bi; Mian Li; Tiange Wang; Linhong Wang; Yong Jiang; Meng Dai; Jieli Lu; Min Xu; Yichong Li; Nan Hu; Jianhong Li; Shengquan Mi; Chung-Shiuan Chen; Guangwei Li; Yiming Mu; Jiajun Zhao; Lingzhi Kong; Jialun Chen; Shenghan Lai; Weiqing Wang; Wenhua Zhao; Guang Ning
Journal:  JAMA       Date:  2013-09-04       Impact factor: 56.272

3.  Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study.

Authors:  Dennis R Cryer; Savian P Nicholas; David H Henry; Donna J Mills; Bruce V Stadel
Journal:  Diabetes Care       Date:  2005-03       Impact factor: 19.112

Review 4.  Banting lecture 1988. Role of insulin resistance in human disease.

Authors:  G M Reaven
Journal:  Diabetes       Date:  1988-12       Impact factor: 9.461

5.  A new pacemaker algorithm for the treatment of atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT).

Authors:  Mark D Carlson; John Ip; John Messenger; Scott Beau; Steven Kalbfleisch; Pierre Gervais; Douglas A Cameron; Aurelio Duran; Jesus Val-Mejias; Judith Mackall; Michael Gold
Journal:  J Am Coll Cardiol       Date:  2003-08-20       Impact factor: 24.094

6.  Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population.

Authors:  Mona Mojtahedzadeh; Martin L Lee; Theodore C Friedman
Journal:  J Diabetes Complications       Date:  2015-07-02       Impact factor: 2.852

7.  Pro-inflammatory and pro-oxidant status of pancreatic islet in vitro is controlled by TLR-4 and HO-1 pathways.

Authors:  Kevin Vivot; Allan Langlois; William Bietiger; Stéphanie Dal; Elodie Seyfritz; Michel Pinget; Nathalie Jeandidier; Elisa Maillard; Jean-Pierre Gies; Séverine Sigrist
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

8.  Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.

Authors:  Jay S Skyler; Richard Bergenstal; Robert O Bonow; John Buse; Prakash Deedwania; Edwin A M Gale; Barbara V Howard; M Sue Kirkman; Mikhail Kosiborod; Peter Reaven; Robert S Sherwin
Journal:  Diabetes Care       Date:  2008-12-17       Impact factor: 17.152

9.  Assessment of Insulin Resistance in Subjects with Normal Glucose Tolerance, Hyperinsulinemia with Normal Blood Glucose Tolerance, Impaired Glucose Tolerance, and Newly Diagnosed Type 2 Diabetes (Prediabetes Insulin Resistance Research).

Authors:  Guang Yang; Chunlin Li; Yanping Gong; Fusheng Fang; Hui Tian; Jian Li; Xiaoling Cheng
Journal:  J Diabetes Res       Date:  2015-12-07       Impact factor: 4.011

10.  Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.

Authors:  Guangwei Li; Ping Zhang; Jinping Wang; Yali An; Qiuhong Gong; Edward W Gregg; Wenying Yang; Bo Zhang; Ying Shuai; Jing Hong; Michael M Engelgau; Hui Li; Gojka Roglic; Yinghua Hu; Peter H Bennett
Journal:  Lancet Diabetes Endocrinol       Date:  2014-04-03       Impact factor: 32.069

View more
  1 in total

1.  Fluorescence Microscopy-Based Quantitation of GLUT4 Translocation: High Throughput or High Content?

Authors:  Verena Stadlbauer; Peter Lanzerstorfer; Cathrina Neuhauser; Florian Weber; Flora Stübl; Petra Weber; Michael Wagner; Birgit Plochberger; Stefan Wieser; Herbert Schneckenburger; Julian Weghuber
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.